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We conducted a meta-analysis of three endometrial cancer 
genome-wide association studies (GWAS) and two follow-up 
phases totaling 7,737 endometrial cancer cases and 37,144 
controls of European ancestry. Genome-wide imputation and 
meta-analysis identified five new risk loci of genome-wide 
significance at likely regulatory regions on chromosomes 
13q22.1 (rs11841589, near KLF5), 6q22.31 (rs13328298, 
in LOC643623 and near HEY2 and NCOA7), 8q24.21 
(rs4733613, telomeric to MYC), 15q15.1 (rs937213, in 
EIF2AK4, near BMF) and 14q32.33 (rs2498796, in AKT1, near 
SIVA1). We also found a second independent 8q24.21 signal 
(rs17232730). Functional studies of the 13q22.1 locus showed 
that rs9600103 (pairwise r2 = 0.98 with rs11841589) is located 
in a region of active chromatin that interacts with the KLF5 
promoter region. The rs9600103[T] allele that is protective 
in endometrial cancer suppressed gene expression in vitro, 
suggesting that regulation of the expression of KLF5, a gene 
linked to uterine development, is implicated in tumorigenesis. 
These findings provide enhanced insight into the genetic and 
biological basis of endometrial cancer.
Endometrial cancer is the fourth most common cancer in women in 
the United States1 and Europe2 and the most common cancer of the 
female reproductive system. The familial relative risk is ~2 (refs. 3,4), 
but highly penetrant germline mutations in mismatch-repair genes5 
and DNA polymerase genes6,7 account for only a small proportion of 
the familial aggregation. Our previous GWAS and subsequent fine-
mapping identified the only two reported genome-wide significant 
risk loci for endometrial cancer, tagged by rs11263763 in HNF1B 
(intron 1)8 and rs727479 in CYP19A1 (intron 4)9.
To identify additional endometrial cancer risk loci, we reanalyzed 
data from our previous GWAS (the Australian National Endometrial 
Cancer Study (ANECS) and Studies of Epidemiology and Risk 
Factors in Cancer Heredity (SEARCH) data sets10) and conducted 
a meta-analysis with two further studies (Supplementary Fig. 1). 
The first study was an independent GWAS, the National Study of 
Endometrial Cancer (NSECG), including 925 endometrial cancer 
cases genotyped using the Illumina 660W Quad array, 1,286 cancer-
free controls from the CORGI/SP1 GWAS11,12 and 2,674 controls 
from the 1958 British Birth Cohort13. The second study comprised 
4,330 endometrial cancer cases and 26,849 controls from Europe, 
the United States and Australia, genotyped using a Custom Illumina 
Infinium iSelect array designed by the Collaborative Oncological 
Gene-environment Study (COGS) initiative14–17 (Supplementary 
Table 1 and Supplementary Note).
We first performed genome-wide imputation using 1000 Genomes 
Project data, allowing us to assess up to 8.6 million variants with 
allele frequency ≥1% across the different studies. Per-allele odds ratios 
and P values for all SNPs in the GWAS and iCOGS analyses were 
obtained using a logistic regression model. There was little evidence 
of systematic overdispersion of the test statistic (λGC = 1.002–1.038; 
Supplementary Fig. 2). A fixed-effects meta-analysis was conducted 
for all 2.3 million typed and well-imputed (info score >0.90) SNPs 
in a total of 6,542 endometrial cancer cases and 36,393 controls. 
The strongest associations were with SNPs in linkage disequilibrium 
(LD) with previously identified risk SNPs for endometrial cancer in 
HNF1B8,10,18 and CYP19A1 (refs. 9,19) (Fig. 1 and Table 1). For four-
teen 1.5-Mb regions containing at least one new SNP with Pmeta <  
1 × 10−5, we performed regional imputation using an additional refer-
ence panel that comprised high-coverage whole-genome sequencing 
data for 196 UK individuals (Supplementary Table 2).
We identified five new regions containing at least one endometrial 
cancer risk SNP with Pmeta < 1 × 10−7 and genotyped the most strongly 
associated SNP in each region in an additional 1,195 NSECG endome-
trial cancer cases and 751 controls using competitive allele-specific 
PCR (KASPar, KBiosciences) and the Fluidigm BioMark System 
(Supplementary Table 3). Duplicate samples displayed concordance 
of >98.5% between different genotyping platforms (Supplementary 
Table 4). All five SNPs were associated with endometrial cancer at 
genome-wide significance (P < 5 × 10−8; Figs. 2 and 3, and Table 1), 
and these associations remained highly significant when analysis was 
restricted to cases with the endometrioid subtype only. Endometrioid-
only analysis did not identify any additional risk loci. Expression 
quantitative trait locus (eQTL) analysis (Online Methods) in normal 
uterine tissue20 and endometrial cancer tumor and adjacent normal 
tissue21 did not yield any SNPs robustly associated with the expression 
of nearby genes at the endometrial cancer risk loci (Supplementary 
Table 5). However, for each risk locus, bioinformatic analysis 
including cell-type-specific expression and histone modification data 
identified correlated SNPs within 500 kb of the lead SNP in likely 
enhancers and multiple potential regulatory targets (Supplementary 
Fig. 3 and Supplementary Table 6). The most compelling candidates 
for future functional analysis are described below.
rs13328298 (odds ratio (OR) = 1.13, 95% confidence interval (CI) = 
1.09–1.18; P = 3.73 × 10−10) at 6q22.31 lies in the long noncoding RNA 
LOC643623, 54 kb upstream of HEY2 and 86 kb upstream of NCOA7. 
Five endometrial cancer risk loci identified through 
genome-wide association analysis
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HEY2 encodes a helix-loop-helix transcrip-
tional repressor in the Notch pathway, which 
maintains stem cells, and dysregulation 
has been associated with different cancers22. 
The NCOA7 protein modulates the activity of the estrogen receptor 
via direct binding23.
The second locus (rs4733613: OR = 0.84, 95% CI = 0.80–0.89; 
P = 3.09 × 10−9) is at 8q24.21. Stepwise conditional logistic regres-
sion identified another independent signal in this region, rs17232730 
(pairwise r2 = 0.02, Pcond = 1.29 × 10−5; Table 2). Both SNPs associated 
with endometrial cancer lie further from MYC (784–846 kb telomeric) 
than most of the other cancer-associated SNPs in the region, includ-
ing those for cancers of the bladder24,25, breast15,26, colorectum12,27, 
ovary28 and prostate29,30. rs17232730 is in moderate LD with the 
rs10088218 SNP for ovarian cancer (r2 = 0.43), with both cancers hav-
ing the same risk allele, but rs4733613 is not in LD (r2 ≤ 0.02) with any 
other cancer-associated SNP in the region (Supplementary Fig. 3). 
A role in tumorigenesis is implicated for several microRNAs (miRNAs) 
in the region31. Of these, miR-1207-5p is reported to repress TERT, 
a locus also implicated in endometrial cancer risk32.
The lead SNP at 15q15 (rs937213: OR = 0.90, 95% CI = 0.86–0.93; 
P = 1.77 × 10−8) lies within an intron of EIF2AK4. EIF2AK4 encodes 
a kinase that phosphorylates EIF2α and downregulates protein syn-
thesis during cellular stress33. Another nearby gene, BMF, encodes 
an apoptotic regulator moderately to highly expressed in glandular 
endometrial tissue34.
At 14q42, the lead SNP rs2498796 (OR = 0.89, 95% CI = 0.85–0.93; 
P = 3.55 × 10−8) lies in intron 3 of the AKT1 oncogene, which is highly 
expressed in the endometrium34. Several SNPs in LD with rs2498796 
are bioinformatically linked with regulation of AKT1 and four other 
nearby genes (SIVA1, ZBTB42, ADSSL1 and INF2; Supplementary 
Fig. 3 and Supplementary Table 6). AKT1 acts in the PI3K–AKT–
mTOR intracellular signaling pathway, which affects cell survival and 
proliferation35 and is activated in endometrial tumors36, especially in 
aggressive disease37–39. SIVA1 encodes an apoptosis regulatory protein 
that inhibits p53 activity40,41 and enhances epithelial–mesenchymal 
transition to promote the motility and invasiveness of epithelial 
cells42. INF2 expression is reported to act as a pro-migratory signal 
in gastric cancer cells treated with mycophenolic acid43.
The final newly identified risk SNP for endometrial cancer was 
rs11841589 (OR = 1.15, 95% CI = 1.11–1.21; P = 4.83 × 10−11) at 
13q22.1, 163 kb and 445 kb downstream of the Krüppel-like factors 
KLF5 and KLF12, respectively. KLF5 is a transcription factor associ-
ated with cell cycle regulation, and it has a role in uterine development, 
homoeostasis and tumorigenesis44–47. Elevated KLF5 levels are strongly 
correlated with activating KRAS mutations48, and KLF5 is targeted for 
degradation by the tumor suppressor FBXW7. Both FBXW7 and KRAS 
are commonly mutated in endometrial cancer49. rs11841589 was one of 
a group of five highly correlated SNPs (r2 ≥ 0.98) surpassing genome-
wide significance in a 3-kb LD block bounded by rs9600103 (P = 8.70 × 
10−11) and rs11841589 (Fig. 4a). There was no residual association 
signal at this locus (Pcond > 0.05) after conditioning on rs11841589. 
Bioinformatic analysis suggested that the causal variant in the inter-
genic 13q22.1 locus may affect a regulatory element that modifies 
KLF5 expression (Supplementary Fig. 3): rs9600103 overlaps a verte-
brate conservation peak and a DNase I hypersensitivity site (DHS) in 
estrogen- and tamoxifen-treated Ishikawa cells in the Encyclopedia of 
DNA Elements (ENCODE)50 (Fig. 4a). In addition, in a Hi-C chroma-
tin capture experiment in HeLa S3 cells51, a chromatin interaction loop 
was observed between a segment containing the KLF5 promoter and the 
rs11841589–rs9600103 locus (P = 0.004; Supplementary Fig. 4).
We further investigated the epigenetic landscape of a 16-kb 
region around rs11841589 and rs9600103 that contained the SNPs 
most strongly associated with endometrial cancer, by analysis of 
three endometrial cancer cell lines: Ishikawa (homozygous for the 
rs9600103[A] and rs11841589[G] high-risk alleles; providing a 
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Figure 1 Manhattan plot from endometrial 
cancer meta-analysis. The Manhattan plot 
shows negative log10-transformed P values from 
meta-analysis over 22 autosomes. There are 
seven loci surpassing genome-wide significance 
(red horizontal line), including two known loci, 
15q21 (CYP19A1) and 17q12 (HNF1B), and 
five new loci, 6q22 (NCOA7 and HEY2), 8q24 
(MYC), 13q22 (KLF5), 14q32 (AKT1 and 
SIVA1) and 15q15 (EIF2AK4 and BMF).
table 1 risk loci associated with endometrial cancer at P < 5 × 10−8 in the meta-analysis
Locus SNP Position (bp)a Nearby gene(s) EAb OAc EAFd
All histologies Endometrioid histology
Allelic OR (95% CI) P I 2 e Allelic OR (95% CI) P I 2 e
Newly identified loci
13q22.1 rs11841589 73,814,891 KLF5, KLF12 G T 0.74 1.15 (1.11–1.21) 4.83 × 10−11 0.19 1.16 (1.10–1.21) 6.01 × 10−10 0.00
6q22.31 rs13328298 126,016,580 HEY2, NCOA7 G A 0.58 1.13 (1.09–1.18) 3.73 × 10−10 0.00 1.15 (1.11–1.20) 1.02 × 10−11 0.00
8q24.21 rs4733613 129,599,278 MYC G C 0.87 0.84 (0.80–0.89) 3.09 × 10−9 0.00 0.84 (0.79–0.89) 7.70 × 10−9 0.09
15q15.1 rs937213 40,322,124 EIF2AK, BMF T C 0.58 0.90 (0.86–0.93) 1.77 × 10−8 0.36 0.90 (0.86–0.94) 2.22 × 10−7 0.30
14q32.33 rs2498796 105,243,220 AKT1, SIVA1 G A 0.70 0.89 (0.85–0.93) 3.55 × 10−8 0.00 0.88 (0.85–0.92) 4.22 × 10−8 0.00
Previously reported loci
17q12 rs11263763 36,103,565 HNF1B A G 0.54 1.20 (1.15–1.25) 2.78 × 10−19 0.37 1.20 (1.15–1.25) 6.51 × 10−17 0.52
15q21 rs2414098 51,537,806 CYP19A1 C T 0.62 1.17 (1.13–1.23) 4.51 × 10−13 0.00 1.18 (1.13–1.23) 2.48 × 10−13 0.00
For all newly identified loci, the lead SNP was either directly genotyped or imputed with an information score of greater than 0.9. HNF1B and CYP19A1 have been previously 
reported by Painter et al.8 and Thompson et al.9.
aPosition is with reference to Build 37 of the reference genome. bEffect allele. cOther allele. dEffect allele frequency. eHeterogeneity I 2 statistic55.
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comparison with the ENCODE data), ARK-2 (homozygous for the 
low-risk T alleles at both SNPs) and AN3CA (a non-KLF5-expressing 
line that is homozygous for the high-risk alleles) (Supplementary 
Fig. 5). We conducted formaldehyde-assisted identification of reg-
ulatory elements (FAIRE; to identify regions of open chromatin) 
and chromatin immunoprecipitation (ChIP) using antibodies 
against dimethylation of histone H3 a lysine 4 (H3K4me2; a marker 
of transcription factor binding52) and pan acetylation of histone H4 
(pan H4ac; a marker of active chromatin). Although ChIP analysis 
with antibody against H4ac did not yield a consistent signal in the 
region, peaks in signals from FAIRE and ChIP with antibody against 
H3K4me2 were specifically present in the KLF5-expressing lines 
and were colocalized with the conservation peak and DHS from the 
ENCODE data at rs9600103, providing strong evidence for open chro-
matin and transcription factor binding at this site (Fig. 4a). We then 
conducted chromatin conformation capture (3C) experiments for the 
KLF5-expressing Ishikawa endometrial cancer cells (Supplementary 
Fig. 5) and found an interaction between the NcoI restriction frag-
ment containing the rs11841589–rs9600103 risk locus SNPs and the 
promoter region of KLF5 (Fig. 4b).
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Figure 2 Forest plots for new endometrial cancer risk loci. The odds ratio and 95% confidence interval (L, lower; U, upper) for the loci in each study 
of the meta-analysis are listed and shown in the adjacent plot. The I2 heterogeneity scores (all <0.4) suggest that there is no marked difference in 
effects between studies. (a) rs11841589 (13q22). (b) rs13328298 (6q22). (c) rs4733613 (8q24). (d) rs17232730 (8q24; pairwise r2 = 0.02 with 
rs4733613). (e) rs937213 (15q15). (f) rs2498796 (14q32).
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We investigated the regulatory nature of 
the region around rs11841589–rs9600103 
using allele-specific luciferase reporter 
assays in Ishikawa cells (Fig. 4c). We used 
paired t tests to compare the activities of 
fragments containing the rs11841589 and 
rs9600103 alleles with that of the pGL3-
Promoter reporter vector (no-insert) con-
trol (Supplementary Table 7). Fragments 
containing the rs9600103[T], rs11841589[T] 
and rs11841589[G] alleles had activity signifi-
cantly lower than that of the pGL3-Promoter 
control (P ≤ 0.014). In contrast, the construct 
containing the rs9600103[A] risk allele had 
luciferase activity similar to that of the pGL3-
Promoter control (P = 0.23) and significantly 
higher than that of the construct with the 
corresponding rs9600103[T] protective 
allele (P = 0.02). These results suggest that the 
endometrial cancer risk tagged by rs11841589 
is at least partly due to a regulatory element 
containing rs9600103 that interacts with the 
KLF5 promoter region, with the rs9600103[A] 
risk allele likely associated with increased gene 
expression.
In summary, this meta-analysis identified five new endometrial 
cancer risk loci at genome-wide significance, bringing the total 
number of common risk loci for endometrial cancer identified by 
GWAS to seven (Fig. 1). Together with other risk-associated SNPs 
reaching study-wide significance32,53,54, these loci explain ~5.1% of 
the familial relative risk for endometrial cancer. These new endome-
trial cancer risk SNPs lie in likely enhancers predicted to regulate gene 
expression for proteins or miRNAs with known or suspected roles in 
tumorigenesis, and we specifically showed that a functional SNP at 
13q22.1 may lie within a transcriptional repressor of KLF5. Our find-
ings further clarify the genetic etiology of endometrial cancer, provide 
Figure 3 Regional association plots for the five 
new loci associated with endometrial cancer. 
(a–f) Negative log10-transformed P values from 
the meta-analysis and regional imputation for 
three GWAS and eight iCOGS groups are shown 
for SNPs at 13q22.1 (a), 6q22 (b), 8q24 (c,d), 
15q15 (e) and 14q32.33 (f). The SNP with 
the lowest P value at each locus is labeled 
and represented by a purple diamond, and dot 
color indicates LD with the top SNP. The blue 
line shows the recombination rate. All plotted 
SNPs were either genotyped or had an IMPUTE 
info score of greater than 0.9 in all data sets. 
Although genome-wide significant results for 
the 14q32.33 locus rely on imputed data, it 
should be noted that there is strong support 
from nearby genotyped markers. Similar regional 
association plots with a larger number of SNPs 
using a less stringent info score cutoff are 
displayed in supplementary Figure 6.
table 2 Conditional analysis of the 8q24 locus showing two independent association signals
SNP Position (bp)a EAb OAc EAFd
Pairwise r 2 with All-histology meta-analysis Conditioning on rs4733613 Conditioning on rs17232730
rs4733613 rs17232730
Allelic  
OR (95% CI) P
Allelic  
OR (95% CI) P
Allelic  
OR (95% CI) P
rs4733613 129,599,278 G C 0.87 – 0.02 0.84  
(0.79–0.89)
5.64 × 10−9 – – 0.86  
(0.81–0.91)
2.32 × 10−7
rs17232730 129,537,746 G C 0.88 0.02 – 1.17  
(1.10–1.24)
4.46 × 10−7 1.14  
(1.08–1.22)
1.29 × 10−5 – –
rs10088218e 129,543,949 G A 0.87 0.02 0.43 1.14  
(1.07–1.20)
1.65 × 10−5 1.12  
(1.05–1.18)
2.92 × 10−4 1.01  
(0.91–1.12)
0.818
aPosition with respect to Build 37 of the reference genome. bEffect allele. cOther allele. dEffect allele frequency. ers10088218 is associated with ovarian cancer (all subtypes), with the associa-
tion being more significant for cancers of serous histology. rs10088218[G] is the risk allele for both endometrial cancer and ovarian cancer.
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regions for functional follow-up and add key information for future 
risk stratification models.
URLs. rmeta, http://cran.r-project.org/web/packages/rmeta/; The 
Cancer Genome Atlas (TCGA), http://www.cancergenome.nih.gov/.
METhodS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Data access was granted by the respective 
management groups of the participating studies, that is, the Australian 
National Endometrial Cancer Study (ANECS), the Queensland 
Institute of Medical Research Controls, the Hunter Community 
Study (HCS), the Studies of Epidemiology and Risk Factors in 
Cancer Heredity (SEARCH), the Wellcome Trust Case Control 
Consortium (WTCCC), the National Study of Endometrial Cancer 
Genetics (NSECG), the Endometrial Cancer Association Consortium 
(ECAC), the Breast Cancer Association Consortium (BCAC) and the 
Ovarian Cancer Association Consortium (OCAC). Genotype data are 
not freely accessible but can be obtained by submitting an appli-
cation to the respective management committees, institutions or 
data owners.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Study overview. Cases and controls were matched as summarized in 
Supplementary Table 1. Each sample set is described in the Supplementary 
Note. The overall study design is illustrated in Supplementary Figure 1.
Additional endometrial cancer GWAS. The National Study of Endometrial 
Cancer Genetics (NSECG) consisted of 925 histologically confirmed endome-
trial cancer cases from the UK (86% with endometrioid-only histology). 
Genotyping was performed using Illumina 660W Quad arrays.
These cases were matched with 1,286 cancer-free controls from the 
UK1/CORGI12 and SP1 (ref. 11) colorectal studies genotyped using Illumina 
Hap550, Hap300 and Hap240S arrays and 1958 Birth Cohort55 controls from 
the Wellcome Trust Case Control Consortium 2 (WTCCC2)13 genotyped 
using Illumina Infinium 1.2M arrays.
Original endometrial cancer GWAS. As described previously, cases with 
endometrioid histology were selected from two population studies; the UK 
Studies of Epidemiology and Risk factors in Cancer Heredity (SEARCH; 
n = 681) and the Australian National Endometrial Cancer Study (ANECS; 
n = 606), and genotypes were generated using Illumina Infinium 610K arrays10. 
In comparison with our previous study10, this meta-analysis analyzed ANECS 
and SEARCH as two groups and included additional controls8,56. SEARCH 
cases were compared with 2,501 controls from the National Blood Service 
(NBS), part of the WTCCC2 controls13. ANECS cases were compared to 
controls recruited as part of the Hunter Community Study56 or Brisbane 
Adolescent Twin Study57, genotyped using Illumina Infinium 610K arrays.
Phase 1 iCOGS genotyping. For the iCOGS genotyping stage, 4,330 women 
with a confirmed diagnosis of endometrial cancer and European ancestry were 
recruited via 11 studies in western Europe, North America and Australia, col-
lectively called the Endometrial Cancer Association Consortium (ECAC).
Healthy female controls with European ancestry and known age at sam-
pling were selected from controls genotyped by the Breast Cancer Association 
Consortium (BCAC)15 or Ovarian Cancer Association Consortium (OCAC)16 
iCOGS projects. Eight case–control groups were matched on the basis of geo-
graphical location, and principal-components analysis (PCA) was conducted; 
individuals who clustered outside the main centroid in pairwise plots of the 
first four principal components were excluded (Supplementary Fig. 7).
Cases and controls were genotyped on a custom Illumina Infinium iSelect 
array with 211,155 SNPs, designed by the Collaborative Oncological Gene-
environment Study (iCOGS), a collaborative project involving four consortia. 
SNPs were included on this array on the basis of promising regions of interest 
in previous breast, ovarian and prostate14 studies and also the 1,483 top SNPs 
from our previous endometrial cancer GWAS10 analysis. Cases and MoMaTEC 
controls were genotyped by the Génome Québec Innovation Center. BCAC 
and OCAC control samples were genotyped at four centers. Raw intensity data 
files for all consortia were sent to the COGS data coordination center at the 
University of Cambridge for centralized genotype calling and quality control, 
so that all case and control genotypes were called using the same procedure.
SNP genotyping array quality control. Genotype calling was performed using 
Illumina’s proprietary Gencall algorithm and Illumnus58. Duplicate samples 
displayed >99% concordance. Standard quality control measures applied 
to genotyping arrays are described in our original GWAS10 and included 
genotypic call rate <0.95; deviation from Hardy–Weinberg equilibrium at 
P < 1 × 10−6; and visual inspection of cluster plots for most significant SNPs. 
For iCOGS, all endometrial cancer cases and MoMaTEC controls were geno-
typed by the Génome Québec Innovation Center. BCAC and OCAC control 
samples were genotyped at four centers. Raw intensity data files for all con-
sortia were sent to the COGS data coordination center at the University of 
Cambridge for centralized genotype calling and quality control, so that all 
case and control genotypes were called using the same procedure. Duplicate 
samples for quality control showed a concordance of >99%. Samples were 
excluded on the basis of the following measures: missingness >5%, heterozygos-
ity rates ((N-O)/N) >5 s.d. from the mean, X-chromosome heterozygosity rate 
(PLINK F score) >0.2 and pairwise identity by descent (IBD) >0.1875 (cutoff 
for second-degree relatives). PCA was conducted using EIGENSTRAT59  
software. Analysis was conducted using PLINK60 and the R packages GenABEL 
and SNPMatrix61,62.
Phase 2 NSECG genotyping. A second genotyping phase consisted of assay-
ing five SNPs with P < 1 × 10−7 and IMPUTE info scores >0.94 from the 
NSECG–ANECS–SEARCH–iCOGS meta-analysis; samples were NSECG 
cases and controls not previously used in the NSECG GWAS or NSECG 
iCOGS. Genotyping was conducted using competitive allele-specific PCR 
(KASPar, KBiosciences) and the Fluidigm BioMark HD System, using standard 
protocols. The genotyping call rate was >0.98, and there was a >0.985 concord-
ance between different genotyping platforms (Supplementary Table 4). There 
was no significant deviation from Hardy–Weinberg equilibrium (P > 0.05). 
Sequences for genotyping primers are listed in Supplementary Table 8.
Genome-wide and regional imputation. Genome-wide imputation for all 
SNP-array-generated data was conducted using IMPUTE (v2)63 and the 1000 
Genomes Project (2012 release) as reference panel. For the first-pass genome-
wide analysis, we prephased chromosomes using SHAPEIT64 to improve the 
computational speed. Imputation was carried out separately for each of the 
three GWAS (for each GWAS, the cases and controls were imputed together 
as a single data set, using only SNPs that passed quality control in both cases 
and controls) and for the iCOGS study (all studies within iCOGS were imputed 
together). SNPs with MAF <0.1% were removed from all studies before impu-
tation. Genome-wide imputation produced 9,594,066 SNPs with MAF ≥1% 
and info ≥0.4 in at least one of the three GWAS and eight iCOGS groups. Of 
these, 8,308,423 SNPs met these criteria in all studies. The iCOGS genotyping 
array (~200,000 SNPs) is aimed at capturing previously prioritized cancer-
associated SNPs and not genome-wide coverage, but nonetheless 8,631,871 
SNPs met the criteria of MAF ≥1% and info ≥0.4, of which 5,437,135 had info 
≥0.7 and 2,333,040 had info ≥0.9.
Regional imputation of regions of interest (1.5-Mb region around SNPs 
with meta-analysis P <1 × 10−5) used both 1000 Genomes Project 2012 release 
and 196 high-coverage, whole-genome-sequenced UK individuals as reference 
panels as a means to improve imputation accuracy65. All SNPs reported in this 
study had an info score ≥0.9 in all data sets.
Association testing. Association testing was carried out using SNPTEST 
(v2)66 employing frequentist tests with a logistic regression model for each of 
the 11 groups as matched in Supplementary Table 1. There was little evidence 
of systematic overdispersion of the test statistic from the quantile–quantile 
plots (Supplementary Fig. 2) and the genomic inflation λGC, calculated using 
all genotyped SNPs passing quality control for the three GWAS. For iCOGS, 
105,000 SNPs after LD pruning (r2 <0.2) and >500 kb from the 1,483 endome-
trial cancer prioritized SNPs on the iCOGS were used.
λGC was between 1.002 and 1.038 for each study. Conditional logistic regres-
sion analysis was conducted for each locus of genome-wide significance using 
SNPTEST to look for the presence of multiple independent association signals. 
This was carried out in a stepwise manner, first conditioning for the most 
significant SNP and subsequently for any SNPs that remained significant 
at Pcond < 1 × 10−4. Regional association plots (Fig. 1 and Supplementary 
Fig. 6) were created using LocusZoom67.
Meta-analysis. Inverse variance, fixed-effects meta-analysis of the 11 
groups (3 GWAS and 8 iCOGS groups) was conducted using GWAMA68. 
The per-allele effect size of each SNP in a particular study is represented by 
β (the log-transformed odds ratio) and its standard error. Between-study 
differences are represented by the I2 heterogeneity score69,70. Forest plots 
of the genome-wide significant loci (Fig. 2) representing risk effects across 
different studies were generated using rmeta. A random-effects meta-analysis 
was also performed for SNPs with I2 >0.3. The results of the second replica-
tion phase (NSECG replication) were subjected to meta-analysis in a 12-way 
meta-analysis for the top five SNPs yielding a total of 7,737 endometrial cancer 
cases and 37,144 controls. 6,635 (86%) of the endometrial cancer cases had 
endometrioid-only histology, and association testing and meta-analysis were 
also conducted with just these samples.
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Bioinformatic analysis and functional annotation of genome-wide 
significant risk loci. The five new genome-wide significant loci and SNPs 
in LD (r2 >0.7 in the European 1000 Genomes Project population) were 
annotated using HaploRegV2 (ref. 71), RegulomeDB72 and data from 
ENCODE50 in Supplementary Table 6. These include information such as 
promoter and enhancer histone marks, DHSs, bound proteins, altered motifs, 
GENCODE and dbSNP annotations, RegulomeDB score and phastCons 
conservation scores.
The bioinformatic analysis in Supplementary Figure 3 used data sets 
described by Hnisz et al.73 and Corradin et al.74 to identify likely enhancers 
in a cell-type-specific context for the risk loci. Enhancer–gene interactions 
are predicted by identifying ‘super-enhancers’ (regions containing neighbor-
ing H3K27ac modifications) from 86 cell and tissue types, and the expressed 
transcript with the transcription start site closest to the center of the 
super-enhancer was then assigned as the target gene. PresTIGE pairs cell-type-
specific H3K4me1 and gene expression data from 13 cell types to identify likely 
enhancer–gene interactions.
Endometrial tissue expression quantitative trait loci analysis for associ-
ated SNPs using GTEx and TCGA data. Publicly available data generated by 
the Genotype-Tissue Expression (GTEx) Project20 and The Cancer Genome 
Atlas (TCGA) were accessed to examine tissue-specific eQTLs. For GTEx, 
expression and genotype data were generated from 70 normal uteri from 
post-mortem biopsies, using an Affymetrix Expression array and Illumina 
Omni 5M SNP array. GTEx provided processed results, evaluating association 
between genotype and expression data. The expression levels are represented 
as a rank-normalized score. TCGA genotype and copy number variation 
(CNV) data were derived from Affymetrix 6.0 SNP arrays. Expression data 
were from RNA-seq arrays (Illumina HiSeq and Illumina Genome Analyzer) 
for 458 endometrial cancer tissues and 30 adjacent normal endometrial tissues. 
Association analyses for TCGA data sets were performed as follows. Genes 
within 500 kb flanking our SNPs of interest were selected for analysis. Because 
there may be significant variation in tumor tissue copy number, somatic CNVs 
were taken into account by regressing gene expression to average copy number 
spanning the gene. Residual unexplained variance in gene expression was then 
regressed on the genotype of the lead SNP at each locus, using genotyped or 
imputed data. Statistical comparisons were subject to Bonferroni correction for 
number of tests (number of sample sets and number of genes assessed).
DNA and RNA extraction from cell lines. Cell lines from the laboratory of 
D. Church, acquired as gifts from B. Weigelt (currently at the Memorial Sloan 
Kettering Cancer Center) and K. Dedes (University of Zurich), were routinely 
tested for mycoplasma contamination. Somatic mutation data generated previ-
ously match those reported in publicly available resources and the literature, 
where available. Cells were snap frozen with dry ice after centrifugation, and 
DNA and RNA were extracted using DNeasy and RNeasy mini kits (Qiagen). 
Nucleic acids were quantified using Nanodrop 2000 (Thermo Scientific) 
spectrophotometry.
Quantification of KLF5 expression in endometrial cancer cell lines. 
Extracted RNA was treated with DNase I, and cDNA was reverse transcribed 
from RNA using the High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). TaqMan Gene Expression Assays were used for KLF5 and GAPDH 
(details available upon request). The absolute expression of KLF5 was quanti-
fied using qRT–PCR on the ABI 7900HT cycler (Applied Biosystems), and the 
critical threshold was manually set at 0.2. Relative expression was calculated 
using the ∆∆Ct method described by Livak and Schmittgen75, with GAPDH 
as an endogenous control.
Formaldehyde-assisted identification of regulatory elements. FAIRE was 
conducted using a method adapted from Giresi et al.76. Briefly, cross-linking 
was performed on a rocker at room temperature. 1% formaldehyde was added 
to ~1 × 108 cells for 5 min, and 115 mM glycine was added to inhibit cross-
linking. For each cell line, a non-cross-linked control was prepared in parallel 
for all remaining steps. After two rinses with 4 °C PBS, cells were suspended in 
successive buffers: lysis buffer I (50 mM HEPES-KOH, 140 mM NaCl, 1 mM 
EDTA, 10% glycerol, 0.5% NP-40 and 0.25% Triton X-100); lysis buffer II 
(10 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA and 0.5 mM EGTA); lysis buffer III 
(10 mM Tris-HCl, 2.1 M NaCl, 1 mM EDTA, 0.1% sodium deoxycholate and 
0.5% N-lauroylsarcosine). Cells were incubated on a rocker at 4 °C for 10 min 
in each lysis buffer, then spun down at 1,300g for 5 min, and the supernatant 
was removed. The cells were then sonicated using the Bioruptor in 7 to 15 30-s 
cycles to generate fragments 100–1,000 bp in size, and gel electrophoresis in 
1% agarose was used to confirm DNA fragment sizes. The DNA was extracted 
with a standard phenol–chloroform method and ethanol precipitated. 50 ng 
of DNA from paired cross-linked and non-cross-linked cells was analyzed in 
duplicate by SYBR Green qPCR using primers at ~1-kb intervals in the 13q22.1 
region downstream of KLF5 (Supplementary Table 8). The ∆∆Ct method31 
was used to normalize results to the input DNA from non-cross-linked cells 
and then expressed relative to the rhodopsin promoter as negative control. 
For each experiment, there were two replicates for the cross-linked cells and 
non-cross-linked controls, each performed on two occasions.
Cross-linked chromatin immunoprecipitation. About 1 × 108 cells were 
cross-linked using 1% formaldehyde for 10 min. Glycine was used to stop 
the cross-linking, cells were then rinsed twice in PBS and cell scrapers were 
used to detach cells adhered to the Petri dish surface. Cells were then resus-
pended in lysis buffer (1% SDS, 10 mM EDTA (Ambion) and 50 mM Tris-HCl 
(Ambion)), incubated for 10 min and then sonicated using the Bioruptor 
(Diagenode) in 7 to 15 30-s cycles to generate fragments 1,000–1,500 bp in size. 
Gel electrophoresis in 1% agarose confirmed the size of the DNA fragments. 
The fragmented DNA was then diluted ten times to the immunoprecipitation 
dilution buffer (1% Triton X-100, 2 nM EDTA, 20 mM Tris-HCl and 150 mM 
NaCl), and each cell line was separated into four tubes: input chromatin, 
no-antibody control and one tube for each antibody. Five microliters of anti-
body to H3K4me2 (Millipore, 07-030) and acetylated histone H4 (Millipore, 
06-866) was added to the antibody tubes and, along with the no-antibody 
control, incubated overnight at 4 °C for immunoprecipitation. The input chro-
matin was kept refrigerated at 4 °C until the reverse cross-linking on day 2. 
Phenylmethylsulfonyl fluoride and protease inhibitors were added to the lysis 
buffer and immunoprecipitation dilution buffer to deactivate proteases, and 
sodium butyrate was added to these solutions to inhibit histone deacetylases. 
Five microliters of protein A Dynabeads was added to each tube, and beads 
were incubated for 4 h. A series of washes were performed using Tris-sucrose-
EDTA (TSE) I (1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 150 mM 
NaCl and 0.1% SDS), TSE II (1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, 500 mM NaCl and 0.1% SDS), Buffer III (0.25 M lithium chloride, 1 mM 
EDTA, 10 mM Tris-HCl, 1% tergitol-type NP-40 and 1% sodium deoxycholate) 
and Tris-EDTA (1×). Three hundred microliters of extraction solution (1% 
SDS 0.1 M sodium bicarbonate) was added, and Dynabeads were removed 
after a 30-min incubation. Then, 0.7 M NaCl was added and reverse cross-
linking occurred overnight at 65 °C. DNA was purified using the QIAquick 
PCR purification kit (Qiagen). One microliter of DNA was analyzed in dupli-
cate or triplicate by SYBR Green qPCR as above, and the ∆∆Ct method was 
used to identify areas with enrichment. For each experiment, there were two 
replicates for each antibody along with the input and no-antibody control, 
each performed on two occasions. Sequences for the primers used are listed 
in Supplementary Table 8.
Chromatin conformation capture. Experiments were performed as described 
in Ghoussaini et al.77, using the KLF5-expressing Ishikawa endometrial can-
cer cell line from the American Type Culture Collection. The cell line was 
authenticated using short-tandem-repeat (STR) profiling, and routinely tested 
for mycoplasma contamination (QIMR Berghofer in-house Support Services). 
Briefly, Ishikawa cells were cross-linked with 1% formaldehyde for 10 min, 
the reaction was quenched with 125 mM glycine, and cells were washed 
with PBS and collected by scraping. Cells were lysed for 30 min on ice in 
10 mM Tris-HCl, pH 7.5, 10 mM NaCl and 0.2% Igepal with protease inhibi-
tors and homogenized in a Dounce homogenizer. Nuclei were pelleted and 
resuspended in 1 ml of 1.2× restriction buffer (NEB 3.1) with 0.3% SDS for 
1 h at 37 °C. 2% Triton X-100 was added, and 1,000 U NcoI was then added 
three times over 24 h at 37 °C with shaking. The enzyme was inactivated, 
and digested DNA was diluted 8× before ligation with 4,000 U of T4 DNA 
ligase overnight at 16 °C. Cross-links were reversed by proteinase K digestion 
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at 65 °C overnight, and DNA was purified by phenol–chloroform extraction 
and ethanol precipitation. The final DNA pellet was dissolved in 10 mM Tris 
(pH 7.5) and purified through Amicon Ultra 0.5-ml columns (Millipore). 3C 
interactions were quantified by SYTO9 qPCR (performed on a RotorGene 
6000) using primers designed to amplify across ligated NcoI restriction frag-
ments with one constant primer within the risk fragment (including rs11841589 
and rs9600103) and a series of test primers within NcoI fragments spanning 
76 kb of the KLF5 promoter region. BAC clones (RP11-81D9 and 
RP11-179I20) covering the region were digested with NcoI, ligated with T4 
ligase and used to determine PCR efficiency. 3C analyses were performed on 
three independent 3C libraries, with each data point in duplicate. Data were 
normalized to the signal from the BAC clone library and from a non-interacting 
chromosomal region using the ∆∆Ct method with incorporated individual 
primer pair efficiencies.
Luciferase reporter assays. For luciferase reporter assays, the regions chr. 13 
73,810,509–73,813,452 around rs9600103 and chr. 13: 73,813,268–73,816,290 
around rs11841589 were cloned into the pGL3-Promoter vector (Promega) to 
test for regulatory effects in Ishikawa cells. Ishikawa cells were selected because 
they express KLF5, showed evidence of a DHS, FAIRE and H3K4me2 enrich-
ment at rs9600103, and were readily transfectable. Site-directed mutagenesis 
was used so both the high- and low-risk alleles of rs9600103 and rs11841589 
were tested. After sequencing to verify the correct insert sequences, cells were 
transiently cotransfected using Lipofectamine with the appropriate pGL3-
Promoter constructs, and the Renilla luciferase pGL4.75 vector (Promega) as 
control for transfection efficiency. After 48 h, luciferase activity was measured 
(Dual-Glo Luciferase Assay System, Promega), and after subtracting back-
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